Widely Prescribed Painkiller Tramadol Offers Minimal Relief, Carries Significant Risks, New Research Finds
Table of Contents
A comprehensive analysis of existing research reveals that tramadol, a commonly prescribed opioid for chronic pain, provides only modest pain relief and is linked to a significantly increased risk of serious side effects, including heart problems. Published online in BMJ Evidence Based Medicine, the findings raise serious questions about the continued widespread use of the drug.
A growing body of evidence suggests that the potential harms of tramadol likely outweigh its limited benefits, prompting calls for a substantial reduction in its prescription rates.
The Rise of Tramadol and Previous Research Gaps
Tramadol is a dual-action opioid frequently prescribed by physicians for moderate to severe acute and chronic pain. Its inclusion in several clinical guidelines for pain management has contributed to a sharp increase in prescriptions in recent years, making it one of the most frequently used opioids in the United States. This growth, researchers note, may be fueled by a perception that tramadol carries fewer side effects and is less addictive than other short-acting opioids.
However, previous systematic reviews have lacked a comprehensive evaluation of both tramadol’s effectiveness and safety across various types of chronic pain. This gap in knowledge left critical questions unanswered regarding the drug’s true risk-benefit profile.
Rigorous Analysis of Nearly 6,500 Participants
To address these uncertainties, researchers conducted a thorough review of randomized clinical trials published up to February 2025. These studies compared tramadol to a placebo in individuals experiencing chronic pain, including those with cancer-related pain.
The final analysis encompassed 19 clinical trials involving a total of 6,506 participants. The trials focused on several specific pain conditions: five examined neuropathic pain, nine focused on osteoarthritis, four looked at chronic low back pain, and one studied fibromyalgia. Participants had an average age of 58, ranging from 47 to 69. Treatment durations varied from 2 to 16 weeks, with follow-up periods lasting 3 to 15 weeks.
Minimal Pain Reduction, Doubled Risk of Harm
The combined data revealed that while tramadol did reduce pain, the improvement was slight and did not meet the thresholds considered clinically meaningful.
More concerningly, an analysis of eight trials tracking serious side effects over 7 to 16 weeks showed that tramadol was associated with approximately double the risk of harm compared to the placebo. This increased risk was primarily driven by a higher incidence of cardiac events, including chest pain, coronary artery disease, and congestive heart failure.
The research also indicated a potential link between tramadol use and an elevated risk of certain cancers, although researchers cautioned that the relatively short follow-up periods make this finding “questionable.”
Common Side Effects and Study Limitations
Across all trials, tramadol was linked to a greater risk of milder side effects, such as nausea, dizziness, constipation, and sleepiness.
The authors acknowledge that many of the study outcomes were at high risk of bias, suggesting that the benefits of tramadol may be overstated while its harms are understated.
The Broader Opioid Crisis
The findings arrive against the backdrop of a global opioid crisis. Researchers emphasize the devastating impact of opioid use, noting that approximately 60 million individuals worldwide experience the addictive effects of these drugs. In 2019, drug use contributed to roughly 600,000 deaths globally, with opioids implicated in nearly 80% of these fatalities and overdoses accounting for 25% of them.
In the United States alone, opioid-related overdose deaths surged from 49,860 in 2019 to 81,806 in 2022. Given these alarming trends and the present research findings, the researchers strongly advocate for minimizing the use of tramadol and other opioids to the greatest extent possible.
The team concluded: “Tramadol may have a slight effect on reducing chronic pain (low certainty of evidence) while likely increasing the risk of both serious (moderate certainty of evidence) and non-serious adverse events (very low certainty of evidence). The potential harms associated with tramadol use for pain management likely outweigh its limited benefits.”
